Irritable bowel syndrome after Clostridioides difficile infection
DOI:
https://doi.org/10.15386/mpr-2832Keywords:
post-infectious irritable bowel syndrome, Clostridioides difficile infection, polymerase chain reaction, epidemiologyAbstract
Background. Irritable bowel syndrome (IBS) is a chronic functional disorder characterized by abdominal pain, bloating, and altered bowel habits. Postinfectious IBS (PI-IBS) develops after acute gastroenteritis, including Clostridioides difficile infection (CDI). While CDI has been shown to decrease in prevalence during the pandemic era, studies indicate a substantial risk of PIIBS following CDI, data remaining limited. The aim of the present study was to evaluate the risk of PI-IBS following a CDI and a potential correlation between PI-IBS onset and the severity of CDI.
Methods. This cross-sectional study included 69 patients hospitalized with suspected CDI at a tertiary center for Infectious Diseases, in Romania. Inclusion criteria were: patients >18 years of age with confirmed CDI via polymerase chain reaction. The severity of CDI was assessed based on hospitalization, laboratory
parameters, and clinical symptoms. PI-IBS was evaluated six months after CDI using the Rome IV IBS questionnaire and the Bristol Stool Form Scale. Relative risk (RR) was calculated using SPSS software and a p value <0.05 was considered significant.
Results. Among the 38 enrolled patients, 24/38 (63%) were males, while 14/38 (37%) were females. The CDI was confirmed in 14/38 (37%) patients by PCR and the infection was ruled out in 24/38 (63%) patients (control group). PIIBS developed in 57% of the CDI group compared to 25% in the control group (RR=2.29, 95% CI 0.99–5.23, p=0.04). CDI severity correlated with higher PIIBS risk, with 90% of hospitalized CDI patients developing PI-IBS (RR=2.72, p=0.0493).
Conclusion. PI-IBS occurred in over half of the patients six months after CDI, with disease severity increasing the PI-IBS risk. These findings highlight the need for proactive management in severe CDI cases to prevent long-term gastrointestinal complications.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Medicine and Pharmacy Reports

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
The authors are required to transfer the copyright of the published paper to the journal. This is done by agreeing to sign the Copyright Assignment Form. Whenever the case, authors are also required to send permissions to reproduce material (such as illustrations) from the copyright holder.
The papers published in the journal are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.